keyword
MENU ▼
Read by QxMD icon Read
search

classical hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/28334025/hla-expression-and-hla-type-associations-in-relation-to-ebv-status-in-hispanic-hodgkin-lymphoma-patients
#1
Luke B Fletcher, Rianne N Veenstra, Eric Y Loo, Amie E Hwang, Imran N Siddiqi, Lydia Visser, Bouke G Hepkema, Ilja M Nolte, Anke van den Berg, Wendy Cozen, Arjan Diepstra
A proportion of classical Hodgkin lymphomas harbor the Epstein Barr virus (EBV). We previously demonstrated that associations between Human Leukocyte Antigen (HLA) alleles and susceptibility to EBV+ classical Hodgkin lymphoma differ between European and Chinese populations. Data on Hispanic populations is missing. Here we examined the association between HLA type, tumor cell HLA expression and other characteristics in Hispanic Hodgkin lymphoma patients. Hispanic Hodgkin lymphoma patients diagnosed at the Los Angeles County-University of Southern California Medical Center from 2000-2012 were included (n = 65)...
2017: PloS One
https://www.readbyqxmd.com/read/28327905/phase-ii-study-of-idelalisib-a-selective-inhibitor-of-pi3k%C3%AE-for-relapsed-refractory-classical-hodgkin-lymphoma
#2
A K Gopal, M A Fanale, C H Moskowitz, A R Shustov, S Mitra, W Ye, A Younes, A J Moskowitz
Background: The phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor idelalisib has been shown to block downstream intracellular signaling, reduce the production of prosurvival chemokines and induce apoptosis in classical Hodgkin lymphoma (HL) cell lines. It has also been shown to inhibit regulatory T cells and myeloid-derived suppressor cells in other tumor models. We hypothesized that inhibiting PI3Kδ would have both direct and indirect antitumor effects by directly targeting the malignant cells as well as modulating the inflammatory microenvironment...
January 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28318345/novel-agents-in-classical-hodgkin-lymphoma
#3
Sven Borchmann, Bastian von Tresckow
Classical Hodgkin lymphoma (cHL) is the most common hematological malignancy in young adults and can be cured in most cases. However, relapsed and refractory Hodgkin lymphoma, certain patient groups, such as elderly patients, and toxicity of first-line treatment still pose significant challenges. Consequently, new treatment options are needed. Recently, many new treatment concepts have been evaluated in clinical trials. Targeted drug-antibody conjugates and immune checkpoint inhibitors have decisively changed treatment approaches...
March 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28294688/successful-treatment-of-classical-hodgkin-lymphoma-during-pregnancy-in-malawi
#4
Edwards Kasonkanji, Bongani Kaimila, Amy Amuquandoh, Maria Chikasema, Blessings Tewete, Toon van der Gronde, Satish Gopal
No abstract text is available yet for this article.
February 7, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28268254/plasma-epstein-barr-virus-dna-for-pediatric-burkitt-lymphoma-diagnosis-prognosis-and-response-assessment-in-malawi
#5
Katherine D Westmoreland, Nathan D Montgomery, Christopher C Stanley, Nader Kim El-Mallawany, Peter Wasswa, Toon van der Gronde, Idah Mtete, Mercy Butia, Salama Itimu, Mary Chasela, Mary Mtunda, Coxcilly Kampani, N George Liomba, Tamiwe Tomoka, Bal M Dhungel, Marcia K Sanders, Robert Krysiak, Peter Kazembe, Dirk P Dittmer, Yuri Fedoriw, Satish Gopal
Point-of-care tools are needed in sub-Saharan Africa (SSA) to improve pediatric Burkitt lymphoma (BL) diagnosis and treatment. We evaluated plasma Epstein-Barr virus (pEBV) DNA as a pediatric BL biomarker in Malawi. Prospectively enrolled children with BL were compared to classical Hodgkin lymphoma (cHL) and non-lymphoma diagnoses. Pediatric BL patients received standardized chemotherapy and supportive care. pEBV DNA was measured at baseline, mid-treatment, and treatment completion. Of 121 assessed children, pEBV DNA was detected in 76/88 (86%) with BL, 16/17 (94%) with cHL, and 2/16 (12%) with non-lymphoma, with proportions higher in BL versus non-lymphoma (p<0...
March 7, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28267244/a-multicenter-phase-ii-study-of-nivolumab-in-japanese-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma
#6
Dai Maruyama, Kiyohiko Hatake, Tomohiro Kinoshita, Noriko Fukuhara, Ilseung Choi, Masafumi Taniwaki, Kiyoshi Ando, Yasuhito Terui, Yusuke Higuchi, Yasushi Onishi, Yasunobu Abe, Tsutomu Kobayashi, Yukari Shirasugi, Kensei Tobinai
Overexpression of programmed death-1 (PD-1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD-1-blocking antibody that inhibits the PD-1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in 17 Japanese patients with refractory/relapsed classical Hodgkin lymphoma previously treated with brentuximab vedotin. Sixteen patients were included in efficacy analyses and 17 in safety analyses. The primary endpoint was the centrally assessed objective response rate (ORR)...
March 7, 2017: Cancer Science
https://www.readbyqxmd.com/read/28249824/a-new-construct-of-antibody-drug-conjugates-for-treatment-of-b-cell-non-hodgkin-s-lymphomas
#7
Libin Zhang, Yixin Fang, Jindřich Kopeček, Jiyuan Yang
The aim of this study was to develop a new class of antibody-drug conjugates (ADCs) with the potential to not only enhance treatment efficacy but also improve tolerability for patients with B-cell lymphomas. Classic ADCs consist of monoclonal antibodies (mAbs) linked to drugs or toxins. They selectively deliver toxic moieties to tumor cells. As such, they greatly improve the therapeutic index compared to traditional chemotherapeutic agents. However, the therapeutic efficacy and safety of ADCs are dependent on linker stability and payload toxicity...
February 26, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28247950/use-of-brentuximab-vedotin-as-salvage-therapy-pre-allogeneic-stem-cell-transplantation-in-relapsed-refractory-cd30-positive-lympho-proliferative-disorders-a-single-centre-experience
#8
Heshani Mediwake, Kirk Morris, Cameron Curley, Jason Butler, Glen Kennedy
AIM: To assess the outcome of use of brentuximab as a bridge to allogeneic stem cell transplant (SCT) in patient with relapsed / refractory CD30+ classic Hodgkin Lymphoma c(HL) and Anaplastic Large Cell Lymphoma (ALCL). METHODS: Outcomes of consecutive patients with relapsed / refractory cHL / ALCL treated with brentuximab as a bridge to SCT were determined by retrospective review of individual medical records. Survival analysis was measured from start of brentuximab treatment...
March 1, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28242522/targeting-the-programmed-death-1-pathway-in-lymphoid-neoplasms
#9
REVIEW
Chi Young Ok, Ken H Young
Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation. Activated effector T-cells, which kill cancer cells, can be affected by PD-1 signaling in some lymphoid neoplasm that express PD-L1 or PD-L2. PD-L1 expression in tumor cells can be induced by extrinsic signal (i.e. interferon gamma) or intrinsic signals, such as genetic aberrations involving 9p24...
March 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28240973/late-relapse-of-classical-hodgkin-lymphoma-an-analysis-of-the-german-hodgkin-study-group-hd7-to-hd12-trials
#10
Paul J Bröckelmann, Helen Goergen, Charlotte Kohnhorst, Bastian von Tresckow, Alden Moccia, Jana Markova, Julia Meissner, Andrea Kerkhoff, Wolf-Dieter Ludwig, Michael Fuchs, Peter Borchmann, Andreas Engert
Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. Patients who experienced a relapse > 5 years into remission were compared with patients in continued remission for > 5 years and with those who experienced a relapse ≤ 5 years after first diagnosis...
February 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28239465/pd-1-blockade-induces-remissions-in-relapsed-classical-hodgkin-lymphoma-following-allogeneic-hematopoietic-stem-cell-transplantation
#11
James Godfrey, Michael R Bishop, Sahr Syed, Elizabeth Hyjek, Justin Kline
BACKGROUND: Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combining these treatments for high-risk hematologic diseases. However, there is concern that checkpoint blockade could augment graft-versus-host disease, and very few studies have evaluated the safety of checkpoint blockade in the post-allogeneic setting. Here, we report the outcomes of three patients with relapsed classical Hodgkin's lymphoma following allogeneic transplant that were treated with the anti-PD-1 antibody, nivolumab...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28220934/advanced-stage-nodular-lymphocyte-predominant-hodgkin-lymphoma-in-children-and-adolescents-clinical-characteristics-and-treatment-outcome-a-report-from-the-sfce-cclg-groups
#12
Ananth G Shankar, Gaelle Roques, Amy A Kirkwood, Anne Lambilliotte, Katja Freund, Thierry Leblanc, Janis Hayward, Samuel Abbou, Alan D Ramsay, Claudine Schmitt, Stephanie Gorde-Grosjean, Hélène Pacquement, Stephanie Haouy, Sabah Boudjemaa, Nathalie Aladjidi, Georgina W Hall, Judith Landman-Parker
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma (nLPHL) is extremely rare in children and as a consequence, optimal treatment for this group of patients has not been established. Here we retrospectively evaluated the treatments and treatment outcomes of 41 of our patients from the UK and France with advanced stage nLPHL. Most patients received chemotherapy, some with the addition of the anti CD20 antibody rituximab or radiotherapy. Chemotherapy regimens were diverse and followed either classical Hodgkin lymphoma or B non-Hodgkin lymphoma protocols...
February 21, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28219001/glut1-as-a-prognostic-factor-for-classical-hodgkin-s-lymphoma-correlation-with-pd-l1-and-pd-l2-expression
#13
Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
BACKGROUND: Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin's lymphoma (cHL). The purpose of this study was to measure the expression of GLUT1 and assess its prognostic significance and potential relationships with PD-L1, programmed death ligand 2 (PD-L2), and programmed death-1 (PD-1) expressions in cHL...
March 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/28212666/classical-hodgkin-lymphoma-masquerading-as-chronic-recurrent-multifocal-osteomyelitis-a-case-report
#14
Michael Pham, Steven Ressler, Allison Rosenthal, Katalin Kelemen
BACKGROUND: Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. CASE PRESENTATION: A 38-year-old white man presented with lower extremity musculoskeletal pain...
February 18, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28208230/emerging-role-of-gsk-3%C3%AE-in-the-pathobiology-of-classical-hodgkin-lymphoma
#15
Claudio Agostinelli, Silvia Carloni, Francesco Limarzi, Simona Righi, Maria Antonella Laginestra, Gerardo Musuraca, Michelangelo Fiorentino, Roberta Napolitano, Antonio Cuneo, Daniele Vergara, Pier Luigi Zinzani, Sabattini Elena, Stefano A Pileri, Serena De Matteis
AIMS: GSK-3β is a serine/threonine kinase involved in glycogen metabolism, cell cycle progression, differentiation, embryogenesis, migration, metabolism, survival and cellular senescence. Its main biological function is to inhibit β-catenin by sequestration and promotion of its proteasomal degradation in the Wnt canonical pathway, however GSK-3β interacts with multiple signaling pathways and aberrant expression of the enzyme was reported in many solid neoplasms. This study aimed to investigate the biological relevance of GSK-3β in classical Hodgkin Lymphomas (cHL)...
February 16, 2017: Histopathology
https://www.readbyqxmd.com/read/28196821/small-lymphocytic-lymphoma-with-reed-sternberg-cells-a-diagnostic-dilemma
#16
S Pervez, B Abro, H Shahbaz
Reed Sternberg (RS) cells in the setting of small lymphocytic lymphoma (SLL) can complicate the histopathological diagnosis. We report a case of a man aged 54 years who presented with cervical lymphadenopathy. Resection of the lymph node was performed and sent for histopathological evaluation to a local laboratory. A diagnosis of SLL with Classic Hodgkin's lymphoma (CHL) was made. The medical oncologist who encountered this diagnosis for the first time sent the biopsy blocks to our laboratory for a second opinion...
February 14, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28196522/xpo1-in-b-cell-hematological-malignancies-from-recurrent-somatic-mutations-to-targeted-therapy
#17
REVIEW
Vincent Camus, Hadjer Miloudi, Antoine Taly, Brigitte Sola, Fabrice Jardin
Many recent publications highlight the large role of the pivotal eukaryotic nuclear export protein exportin-1 (XPO1) in the oncogenesis of several malignancies, and there is emerging evidence that XPO1 inhibition is a key target against cancer. The clinical validation of the pharmacological inhibition of XPO1 was recently achieved with the development of the selective inhibitor of nuclear export compounds, displaying an interesting anti-tumor activity in patients with massive pre-treated hematological malignancies...
February 14, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28191697/composite-lymphoma-of-peripheral-t-cell-lymphoma-and-hodgkin-lymphoma-mixed-cellularity-type-pathological-and-molecular-analysis
#18
Ayako Ichikawa, Hiroaki Miyoshi, Takuji Yamauchi, Fumiko Arakawa, Riko Kawano, Hiroko Muta, Yasuo Sugita, Koichi Akashi, Koichi Ohshima
Composite lymphomas (CLs) are defined as two unrelated lymphomas occurring at the same time within the same tissue. The incidence of these tumors is low. Of all possible combinations between lymphomas, the least frequent are the ones combining peripheral T-cell lymphoma (PTCL) and Hodgkin lymphoma (HL). We recently identified five cases of CL composed of PTCL and classical HL, mixed cellularity type. We investigated histological and clinical features of these cases. Immunostaining was performed on paraffin sections...
February 13, 2017: Pathology International
https://www.readbyqxmd.com/read/28183501/an-unusual-cause-of-pulmonary-nodules-after-stem-cell-transplantation
#19
Anna K Brady, Jonathan R Fromm, Siddhartha G Kapnadak
A man in his 20s with a history of classical Hodgkin's lymphoma was admitted with fever. His original lymphoma diagnosis was made 3 years prior, when he had presented with lymphadenopathy and a mediastinal mass. He had relapsed disease despite chemotherapy and radiation. As a result, he underwent autologous peripheral blood stem cell transplant (SCT) 6 months prior to current presentation and subsequently allogeneic SCT 2 months prior for added graft vs tumor effect.
February 2017: Chest
https://www.readbyqxmd.com/read/28179969/composite-lymphoma-opposite-ends-of-spectrum-meet
#20
Uqba Khan, Tarik Hadid, Warda Ibrar, Dahlia Sano, Ayad Al-Katib
An 18-year-old African-American female presented with an episode of syncope. Initial investigations revealed large lung mass with invasion into right atrium along with lesions in kidneys and liver. Patient also developed superior vena cava syndrome due to lung mass. Biopsy of lung mass revealed diagnosis of composite lymphoma with involvement by primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma. Patient was started on dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) with complete response to treatment...
March 2017: Journal of Clinical Medicine Research
keyword
keyword
49025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"